• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在仓鼠原发性感染模型中,用功能化牛抗体富集乳清治疗和预防复发性艰难梭菌感染。

Treatment and Prevention of Recurrent Clostridium difficile Infection with Functionalized Bovine Antibody-Enriched Whey in a Hamster Primary Infection Model.

机构信息

Chair of Food and Bioprocess Engineering, Technical University of Munich, 85354 Freising, Germany.

ZIEL Institute for Food & Health, Technical University of Munich, 85354 Freising, Germany.

出版信息

Toxins (Basel). 2019 Feb 6;11(2):98. doi: 10.3390/toxins11020098.

DOI:10.3390/toxins11020098
PMID:30736358
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6409564/
Abstract

Toxin-induced infection (CDI) is a major disease characterized by severe diarrhea and high morbidity rates. The aim with this study was to develop an alternative drug for the treatment of CDI. Cows were repeatedly immunized to establish specific immunoglobulin G and A titers against toxins A (TcdA) and B (TcdB) and against cells in mature milk or colostrum. The effect of three different concentrations of anti- whey protein isolates (anti-CD-WPI) and the standard of care antibiotic vancomycin were investigated in an animal model of CD infected hamsters (6 groups, with 10 hamsters each). WPI obtained from the milk of exactly the same cows pre-immunization and a vehicle group served as negative controls. The survival of hamsters receiving anti-CD-WPI was 50, 80 and 100% compared to 10 and 0% for the control groups, respectively. Vancomycin suppressed the growth of and thus protected the hamsters at the time of administration, but 90% of these hamsters nevertheless died shortly after discontinuation of treatment. In contrast, the surviving hamsters of the anti-CD-WPI groups survived the entire study period, although they were treated for only 75 h. The specific antibodies not only inactivated the toxins for initial suppression of CDI, but also provoked the inhibition of growth after discontinuation, thus preventing recurrence. Oral administration of anti-CD-WPI is a functional therapy of CDI in infected hamsters for both primary treatment and prevention of recurrence. Thus, anti-CD-WPI could address the urgent unmet medical need for treating and preventing recurrent CDI in humans.

摘要

产肠毒素性感染(CDI)是一种以严重腹泻和高发病率为特征的主要疾病。本研究的目的是开发一种治疗 CDI 的替代药物。通过反复免疫奶牛,建立针对毒素 A(TcdA)和 B(TcdB)以及成熟乳或初乳中 细胞的特异性免疫球蛋白 G 和 A 滴度。在感染 CD 的仓鼠动物模型中(6 组,每组 10 只),研究了三种不同浓度的抗乳清蛋白分离物(抗-CD-WPI)和标准护理抗生素万古霉素的作用。来自预免疫奶牛乳汁的 WPI 以及载体组作为阴性对照。接受抗-CD-WPI 的仓鼠的存活率分别为 50%、80%和 100%,而对照组的存活率分别为 10%和 0%。万古霉素抑制了 的生长,从而在给药时保护了仓鼠,但 90%的仓鼠在治疗停止后不久仍死亡。相比之下,抗-CD-WPI 组的存活仓鼠在整个研究期间存活下来,尽管它们仅接受了 75 小时的治疗。特异性抗体不仅使毒素失活以抑制 CDI 的初始发作,而且在停药后还引发了 生长的抑制,从而防止了复发。口服抗-CD-WPI 是感染仓鼠 CDI 的功能性治疗方法,可用于初次治疗和预防复发。因此,抗-CD-WPI 可以解决治疗和预防人类复发性 CDI 的迫切未满足的医疗需求。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d03a/6409564/f47ef508b502/toxins-11-00098-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d03a/6409564/644705a23714/toxins-11-00098-g0A1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d03a/6409564/a31c85687220/toxins-11-00098-g0A2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d03a/6409564/7b8ec7d3d20b/toxins-11-00098-g0A3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d03a/6409564/bc9790ae0897/toxins-11-00098-g0A4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d03a/6409564/9e5109030a1b/toxins-11-00098-g0A5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d03a/6409564/df2ad2185fd9/toxins-11-00098-g0A6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d03a/6409564/de1c22933eed/toxins-11-00098-g0A7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d03a/6409564/5cfea32d274c/toxins-11-00098-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d03a/6409564/e805b3ee541f/toxins-11-00098-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d03a/6409564/1146da37a300/toxins-11-00098-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d03a/6409564/78bfca42e6b8/toxins-11-00098-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d03a/6409564/b7e02a2f9fd3/toxins-11-00098-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d03a/6409564/bbb12866dd1e/toxins-11-00098-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d03a/6409564/f47ef508b502/toxins-11-00098-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d03a/6409564/644705a23714/toxins-11-00098-g0A1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d03a/6409564/a31c85687220/toxins-11-00098-g0A2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d03a/6409564/7b8ec7d3d20b/toxins-11-00098-g0A3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d03a/6409564/bc9790ae0897/toxins-11-00098-g0A4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d03a/6409564/9e5109030a1b/toxins-11-00098-g0A5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d03a/6409564/df2ad2185fd9/toxins-11-00098-g0A6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d03a/6409564/de1c22933eed/toxins-11-00098-g0A7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d03a/6409564/5cfea32d274c/toxins-11-00098-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d03a/6409564/e805b3ee541f/toxins-11-00098-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d03a/6409564/1146da37a300/toxins-11-00098-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d03a/6409564/78bfca42e6b8/toxins-11-00098-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d03a/6409564/b7e02a2f9fd3/toxins-11-00098-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d03a/6409564/bbb12866dd1e/toxins-11-00098-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d03a/6409564/f47ef508b502/toxins-11-00098-g007.jpg

相似文献

1
Treatment and Prevention of Recurrent Clostridium difficile Infection with Functionalized Bovine Antibody-Enriched Whey in a Hamster Primary Infection Model.在仓鼠原发性感染模型中,用功能化牛抗体富集乳清治疗和预防复发性艰难梭菌感染。
Toxins (Basel). 2019 Feb 6;11(2):98. doi: 10.3390/toxins11020098.
2
Systemic antibody responses induced by a two-component Clostridium difficile toxoid vaccine protect against C. difficile-associated disease in hamsters.两组分艰难梭菌类毒素疫苗诱导的系统抗体应答可预防仓鼠艰难梭菌相关性疾病。
J Med Microbiol. 2013 Sep;62(Pt 9):1394-1404. doi: 10.1099/jmm.0.056796-0. Epub 2013 Mar 21.
3
Oral Immunization with Nontoxigenic Clostridium difficile Strains Expressing Chimeric Fragments of TcdA and TcdB Elicits Protective Immunity against C. difficile Infection in Both Mice and Hamsters.口服表达 TcdA 和 TcdB 嵌合片段的无毒型艰难梭菌菌株可诱导小鼠和仓鼠产生针对艰难梭菌感染的保护性免疫。
Infect Immun. 2018 Oct 25;86(11). doi: 10.1128/IAI.00489-18. Print 2018 Nov.
4
The protective effect of recombinant Lactococcus lactis oral vaccine on a Clostridium difficile-infected animal model.重组乳球菌口服疫苗对艰难梭菌感染动物模型的保护作用。
BMC Gastroenterol. 2013 Jul 17;13:117. doi: 10.1186/1471-230X-13-117.
5
Development of a recombinant toxin fragment vaccine for Clostridium difficile infection.艰难梭菌感染重组毒素片段疫苗的研发
Vaccine. 2014 May 19;32(24):2812-8. doi: 10.1016/j.vaccine.2014.02.026. Epub 2014 Mar 21.
6
The safety of whey protein concentrate derived from the milk of cows immunized against Clostridium difficile.源自接种艰难梭菌疫苗的奶牛所产牛奶的浓缩乳清蛋白的安全性。
Regul Toxicol Pharmacol. 2007 Apr;47(3):317-26. doi: 10.1016/j.yrtph.2006.12.001. Epub 2007 Feb 12.
7
Novel Clostridium difficile Anti-Toxin (TcdA and TcdB) Humanized Monoclonal Antibodies Demonstrate In Vitro Neutralization across a Broad Spectrum of Clinical Strains and In Vivo Potency in a Hamster Spore Challenge Model.新型艰难梭菌抗毒素(TcdA和TcdB)人源化单克隆抗体在体外对多种临床菌株具有中和作用,并在仓鼠孢子攻击模型中展现出体内效力。
PLoS One. 2016 Jun 23;11(6):e0157970. doi: 10.1371/journal.pone.0157970. eCollection 2016.
8
Clostridium difficile chimeric toxin receptor binding domain vaccine induced protection against different strains in active and passive challenge models.艰难梭菌嵌合毒素受体结合域疫苗在主动和被动攻击模型中诱导了针对不同菌株的保护作用。
Vaccine. 2017 Jul 24;35(33):4079-4087. doi: 10.1016/j.vaccine.2017.06.062. Epub 2017 Jun 29.
9
The recombinant Lactococcus lactis oral vaccine induces protection against C. difficile spore challenge in a mouse model.重组乳酸乳球菌口服疫苗在小鼠模型中诱导对艰难梭菌孢子攻击的保护作用。
Vaccine. 2015 Mar 24;33(13):1586-95. doi: 10.1016/j.vaccine.2015.02.006. Epub 2015 Feb 16.
10
Deciphering the domain specificity of C. difficile toxin neutralizing antibodies.解析艰难梭菌毒素中和抗体的结构特异性。
Vaccine. 2019 Jun 27;37(29):3892-3901. doi: 10.1016/j.vaccine.2019.05.040. Epub 2019 May 20.

引用本文的文献

1
New treatment approaches for infections: alternatives to antibiotics and fecal microbiota transplantation.感染的新治疗方法:抗生素和粪便微生物群移植的替代品。
Gut Microbes. 2024 Jan-Dec;16(1):2337312. doi: 10.1080/19490976.2024.2337312. Epub 2024 Apr 9.
2
Immunization Strategies Against Clostridioides difficile.针对艰难梭菌的免疫策略。
Adv Exp Med Biol. 2024;1435:117-150. doi: 10.1007/978-3-031-42108-2_7.
3
Development and characterization of phage display-derived anti-toxin antibodies neutralizing TcdA and TcdB of .

本文引用的文献

1
Isolation of biofunctional bovine immunoglobulin G from milk- and colostral whey with mixed-mode chromatography at lab and pilot scale.用实验室和中试规模的混合模式色谱法从乳和初乳乳清中分离具有生物功能的牛免疫球蛋白 G。
J Chromatogr A. 2018 Aug 10;1562:59-68. doi: 10.1016/j.chroma.2018.05.046. Epub 2018 May 23.
2
Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA).临床实践指南:成人和儿童艰难梭菌感染:美国传染病学会(IDSA)和美国医疗保健流行病学学会(SHEA) 2017 年更新。
Clin Infect Dis. 2018 Mar 19;66(7):e1-e48. doi: 10.1093/cid/cix1085.
3
噬菌体展示衍生的中和艰难梭菌毒素A和毒素B的抗毒素抗体的开发与表征
Microbiol Spectr. 2023 Sep 5;11(5):e0531022. doi: 10.1128/spectrum.05310-22.
4
Application of recombinant antibodies for treatment of infection: Current status and future perspective.重组抗体在 感染治疗中的应用:现状与展望。
Front Immunol. 2022 Aug 23;13:972930. doi: 10.3389/fimmu.2022.972930. eCollection 2022.
5
Frontiers in antibiotic alternatives for infection.抗感染替代抗生素的前沿。
World J Gastroenterol. 2021 Nov 14;27(42):7210-7232. doi: 10.3748/wjg.v27.i42.7210.
6
Potential Benefits of Bovine Colostrum in Pediatric Nutrition and Health.牛初乳在儿科营养与健康中的潜在益处。
Nutrients. 2021 Jul 26;13(8):2551. doi: 10.3390/nu13082551.
7
Alteration of Intestinal Microbiome of Infected Hamsters during the Treatment with Specific Cow Antibodies.感染仓鼠在接受特定牛抗体治疗期间肠道微生物群的改变
Antibiotics (Basel). 2021 Jun 16;10(6):724. doi: 10.3390/antibiotics10060724.
8
Establishment of an In Vitro System of the Human Intestinal Microbiota: Effect of Cultivation Conditions and Influence of Three Donor Stool Samples.建立人体肠道微生物群的体外系统:培养条件的影响及三个供体粪便样本的作用
Microorganisms. 2021 May 13;9(5):1049. doi: 10.3390/microorganisms9051049.
9
Prevention of Infection and Associated Diarrhea: An Unsolved Problem.感染及相关腹泻的预防:一个未解决的问题。
Microorganisms. 2020 Oct 23;8(11):1640. doi: 10.3390/microorganisms8111640.
10
Anti-virulence strategies for infection: advances and roadblocks.抗感染的抗毒力策略:进展与障碍。
Gut Microbes. 2020 Nov 9;12(1):1802865. doi: 10.1080/19490976.2020.1802865.
Bovine antibodies targeting primary and recurrent Clostridium difficile disease are a potent antibiotic alternative.
针对原发性和复发性艰难梭菌病的牛抗体是一种有效的抗生素替代药物。
Sci Rep. 2017 Jun 16;7(1):3665. doi: 10.1038/s41598-017-03982-5.
4
Rhea: a transparent and modular R pipeline for microbial profiling based on 16S rRNA gene amplicons.Rhea:一个基于16S rRNA基因扩增子的用于微生物谱分析的透明且模块化的R管道。
PeerJ. 2017 Jan 11;5:e2836. doi: 10.7717/peerj.2836. eCollection 2017.
5
Clostridium difficile colitis: pathogenesis and host defence.艰难梭菌结肠炎:发病机制与宿主防御
Nat Rev Microbiol. 2016 Oct;14(10):609-20. doi: 10.1038/nrmicro.2016.108. Epub 2016 Aug 30.
6
Disease Progression and Resolution in Rodent Models of Clostridium difficile Infection and Impact of Antitoxin Antibodies and Vancomycin.艰难梭菌感染啮齿动物模型中的疾病进展与消退以及抗毒素抗体和万古霉素的影响
Antimicrob Agents Chemother. 2016 Oct 21;60(11):6471-6482. doi: 10.1128/AAC.00974-16. Print 2016 Nov.
7
Clostridium difficile infection.艰难梭菌感染。
Nat Rev Dis Primers. 2016 Apr 7;2:16020. doi: 10.1038/nrdp.2016.20.
8
WSES guidelines for management of Clostridium difficile infection in surgical patients.WSES外科患者艰难梭菌感染管理指南。
World J Emerg Surg. 2015 Aug 20;10:38. doi: 10.1186/s13017-015-0033-6. eCollection 2015.
9
Burden of Clostridium difficile infection in the United States.美国艰难梭菌感染的负担
N Engl J Med. 2015 Feb 26;372(9):825-34. doi: 10.1056/NEJMoa1408913.
10
SMT19969 for Clostridium difficile infection (CDI): in vivo efficacy compared with fidaxomicin and vancomycin in the hamster model of CDI.用于艰难梭菌感染(CDI)的SMT19969:在CDI仓鼠模型中与非达霉素和万古霉素相比的体内疗效
J Antimicrob Chemother. 2015;70(6):1757-62. doi: 10.1093/jac/dkv005. Epub 2015 Feb 3.